SOURCE: ON24

ON24

September 28, 2009 08:04 ET

Virtual Conference Features World's Leading H1N1 Flu Vaccine Researchers

Elsevier Vaccine Virtual Congress With ON24 to Facilitate Global Response to Swine Flu Pandemic

SAN FRANCISCO, CA--(Marketwire - September 28, 2009) - ON24, Inc. (http://www.ON24.com), the global leader in webcasting and virtual event solutions, announced today that it is working with Elsevier, a leading publisher of scientific, technical and medical information products and services, and its journal, Vaccine, to offer a virtual alternative to the annual Vaccine Global Congress, being held October 4-6 in Singapore. The interactive Vaccine Virtual Congress will allow researchers and healthcare professionals to sample the same high-quality content and network with peers, all from their own desktops and at a time when collaboration among the world's leading vaccine researchers is especially critical.

With the World Health Organization's recent announcement that global production of swine flu vaccines will not be sufficient to effectively combat the pandemic, the sessions dedicated to the latest H1N1 influenza vaccine research are especially timely; GlaxoSmithKline (GSK) and Novartis, for example, will present their latest data on flu vaccine research. "Because of the Vaccine Virtual Congress and the capabilities of ON24 Virtual Show, we will be able to bring to the global medical community the information they need, assisting in accelerating the development of vaccines and in the coordination of medical response worldwide," said Vaccine Executive Publisher Floris de Hon.

The GSK satellite H1N1 symposium will feature a "who's who" in the medical community, including Albert Osterhaus, who was the first to identify the SARS virus and to detect human infection by the Hong Kong strain of the H5N1 virus, also known as avian influenza. Malik Peiris, the first to identify the agent that causes SARS, will also chair the symposium. The Novartis presentation, "Working around the Clock," will feature new H1N1 clinical trial findings.

The Vaccine Virtual Congress will offer video broadcasts of live and on-demand keynote presentations and related Q&A sessions, scheduled for October 5 and 7, respectively. Virtual delegates will be able to attend presentations by top international speakers, submit questions in real time, network and chat with their online peers and easily navigate the show via ON24's fully interactive virtual platform. In addition, Elsevier will provide on-demand access for six months to select conference webcasts.

"The ability to offer a virtual alternative to the traditional vaccine congress is especially valuable this year," said ON24 CEO Sharat Sharan. "Now the world's leading vaccine authorities can all fully participate in the congress, without the inconvenience and expense of travel. Elsevier is effectively leveraging ON24's leading virtual event technology to facilitate coordination of the efforts of the global medical community at a time when a flu pandemic is looming."

Registration for the Vaccine Virtual Congress is at http://www.vaccinecongress.com/.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About ON24 Virtual Show

ON24 Virtual Show is a flexible communications and demand generation solution that provides a virtual venue for events such as trade shows, partner pavilions, conferences and training summits. With its professional networking capabilities, ON24 Virtual Show makes virtual events more engaging and interactive. Without ever leaving their desks, participants can learn from video presentations, interact with exhibitors and communicate with peers using professional networking tools. In addition, with its complete registration system and ability to track attendee activity, ON24 Virtual Show delivers robust reporting analytics.

About ON24 Inc.

The recognized global virtual events market share leader, ON24 is the world's leading provider of webcasting and virtual environments for corporate communications and demand generation. ON24 offers fully integrated, enterprise-wide solutions for a wide range of applications, including training, conferences, company meetings, partner expos and trade shows. More than 750 organizations in publishing, technology, life sciences, government and financial services, including IBM, Cisco, United Business Media, Credit Suisse, GE Healthcare, Oracle and the National Science Foundation, rely on ON24. The company is headquartered in San Francisco, with offices in New York, London and Singapore. For more information, visit http://www.ON24.com.

Contact Information

  • MEDIA CONTACTS:

    Denise Persson
    ON24, Inc.
    Phone: 415-369-8320
    Email Contact

    Curtis Sparrer
    Connecting Point Communications
    Phone: 415-442-4034
    Email Contact